


# PRODUCT INFORMATION



## Picotamide

Item No. 21690

**CAS Registry No.:** 32828-81-2  
**Formal Name:** 4-methoxy-N<sup>1</sup>,N<sup>3</sup>-bis(3-pyridinylmethyl)-1,3-benzenedicarboxamide  
**MF:** C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>  
**FW:** 376.4  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 212 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Picotamide is supplied as a crystalline solid. A stock solution may be made by dissolving the picotamide in the solvent of choice. Picotamide is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of picotamide in these solvents is approximately 1, 5, and 10 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of picotamide can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of picotamide in PBS, pH 7.2, is approximately 0.2 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Picotamide is an antiplatelet drug that inhibits both thromboxane A<sub>2</sub> (TXA<sub>2</sub>) receptors (K<sub>d</sub> = 325 nM) and TXA<sub>2</sub> synthase.<sup>1,2</sup> It significantly inhibits basal and lipopolysaccharide-stimulated TXA<sub>2</sub> synthesis by rat peritoneal macrophages when used at 0.5 mM.<sup>3</sup> Formulations containing picotamide have potential applications in the reduction of peripheral artery disease in patients with diabetes.<sup>1</sup>

### References

1. Celestini, A. and Violi, F. A review of picotamide in the reduction of cardiovascular events in diabetic patients. *Vasc. Health Risk Manag.* **3(1)**, 93-98 (2008).
2. Modesti, P.A., Cecioni, I., Colella, A., et al. Binding kinetics and antiplatelet activities of picotamide, a thromboxane A<sub>2</sub> receptor antagonist. *Br. J. Pharmacol.* **112(1)**, 81-86 (1994).
3. Matera, G., Chisari, M., Altavilla, D., et al. Selective thromboxane synthetase inhibition by picotamide and effects on endotoxin-induced lethality. *Proc. Soc. Exp. Biol. Med.* **187(1)**, 58-61 (1988).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/27/2018

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM